The Use of Expanded Carrier Screening in Reproductive Medicine: Scientific Impact Paper No. 74.


Journal

BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741

Informations de publication

Date de publication:
05 Jun 2024
Historique:
medline: 6 6 2024
pubmed: 6 6 2024
entrez: 5 6 2024
Statut: aheadofprint

Résumé

Expanded carrier screening (ECS) is a genetic screening test carried out by analysing a blood sample. This screen can be used to detect whether the individual unknowingly carries gene variants associated with common genetic conditions, such as cystic fibrosis, that may be passed on to their children. It is typically performed in reproductive medicine for those who are considering having a family either naturally or via fertility treatment. Many donor sperm and egg banks, particularly in the USA and Europe, also perform blanket ECS testing on all their prospective sperm and egg donors. ECS is not currently routine practice in the UK, but a growing number of patients are requesting it before treatment. All of us carry gene variants of some sort that may cause autosomal recessive disease in their children if their partner or donor also carry a variant in the same gene. An autosomal recessive disease means two copies of an abnormal gene must be present in order for the disease or trait (such as cystic fibrosis or sickle cell disease) to develop. One copy of the variant means the person is a carrier but does not have the condition. Two copies, i.e. from the mother and father, means the child has a 25% chance of having the genetic disease. Carrying a gene variant does not mean that the individual would necessarily have any symptoms of the disease or any features of the condition. Genetic tests for specific conditions are currently available either before or during pregnancy for prospective parents who have a family or personal history of a genetic condition, or for those from ethnic backgrounds where certain conditions - such as haemoglobinopathies (blood disorders) - are common, prompting referral to a clinical genetics department. Expanded carrier screens may test for more than 100 genetic conditions. The list of conditions screened for is called a panel. Common panels are 250 or 600 genes. Not all expanded carrier screens that are available analyse the same genes. Some may test for genes that do not cause serious disease, or cause diseases that occur in later life; others test for genes that cause severe conditions in childhood. There is no agreement as to which panel of genes should be tested for in an ECS. Understanding the screening that is being offered, and the meaning of any results, is complicated and requires support from appropriately trained professionals to best inform the prospective parent or parents.

Identifiants

pubmed: 38839259
doi: 10.1111/1471-0528.17832
doi:

Types de publication

Editorial

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 Royal College of Obstetricians and Gynaecologists.

Références

Mastantuoni E, Saccone G, Al‐Kouatly HB, Paternoster M, D'Alessandro P, Arduino B, et al. Expanded carrier screening: A current perspective. Eur J Obstet Gynecol Reprod Biol. 2018;230:41–54.
Rafi I, Hayward J, Lucassen A. Position Statement on Direct to Consumer Genomic Testing. Royal College of General Practitioners and The British Society for Genetic Medicine. 2019 [cited 2023 May 9]. Available from: https://aegh.org/wp‐content/uploads/2019/11/RCGP‐position‐statement‐on‐direct‐to‐consumer‐genomic‐testing‐oct‐2019.pdf
NHS England. National genomic test directory. NHS; 2018, updated 2023 [cited 2023 May 9]. Available from: https://www.england.nhs.uk/publication/national‐genomic‐test‐directories/
Human Fertilisation & Embryology Authority. Code of Practice. 9th ed. HFEA; 2023 [cited 2024 May 8]. Available from: https://portal.hfea.gov.uk/knowledge‐base/read‐the‐code‐of‐practice/
Abulí A, Costa‐Roger M, Codina‐Solà M, Valenzuela I, Leno‐Colorado J, Rovira‐Moreno E, et al. Experience using singleton exome sequencing of probands as an approach to preconception carrier screening in consanguineous couples. J Med Genet. 2023;60(6):540–546.
Sallevelt SCEH, Stegmann APA, de Koning B, Velter C, Steyls A, van Esch M, et al. Diagnostic exome‐based preconception carrier testing in consanguineous couples: results from the first 100 couples in clinical practice. Genet Med. 2021;23(6):1125–1136.
de Wert G, van der Hout S, Goddijn M, Vassena R, Frith L, Vermeulen N, et al. The ethics of preconception expanded carrier screening in patients seeking assisted reproduction. Hum Reprod Open. 2021;(1):hoaa063.
Gao Z, Waggoner D, Stephens M, Ober C, Przeworski M. An estimate of the average number of recessive lethal mutations carried by humans. Genetics. 2015;199(4):1243–1254.
Chokoshvili D, Vears D, Borry P. Expanded carrier screening for monogenic disorders: where are we now? Prenat Diagn. 2018;38(1):59–66.
Peyser A, Singer T, Mullin C, et al. Comparing ethnicity‐based and expanded carrier screening methods at a single fertility center reveals significant differences in carrier rates and carrier couple rates. Genet Med. 2019;21:1400–1406.
Gregg AR, Aarabi M, Klugman S, Leach NT, Bashford MT, Goldwaser T, et al. Screening for autosomal recessive and X‐linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(10):1793–1806.
Nelson R. ACMG Updates Guidance on Carrier Screening. Am J Med Genet A. 2021;188(1):9–10.
Henneman L, Borry P, Chokoshvili D, Cornel MC, van El CG, Forzano F, et al. Responsible implementation of expanded carrier screening. Eur J Hum Genet. 2016;24(6):e1–e12.
Dondorp W, De Wert G, Pennings G, Shenfield F, Devroey P, Tarlatzis B, et al. ESHRE Task Force on Ethics and Law 21: genetic screening of gamete donors: ethical issues. Hum Reprod. 2014;29(7):1353–1359.

Auteurs

Classifications MeSH